| 前收盘价格 | 1.16 |
| 收盘价格 | 1.18 |
| 成交量 | 101,704 |
| 平均成交量 (3个月) | 176,220 |
| 市值 | 70,935,816 |
| 价格/销量 (P/S) | 0.540 |
| 股市价格/股市净资产 (P/B) | 0.760 |
| 52周波幅 | |
| 利润日期 | 12 Aug 2025 - 18 Aug 2025 |
| 营业利益率 (TTM) | -6,217.44% |
| 稀释每股收益 (EPS TTM) | -3.27 |
| 季度收入增长率 (YOY) | 0.40% |
| 总债务/股东权益 (D/E MRQ) | 6,298.14% |
| 流动比率 (MRQ) | 5.71 |
| 营业现金流 (OCF TTM) | -143.10 M |
| 杠杆自由现金流 (LFCF TTM) | -75.65 M |
| 资产报酬率 (ROA TTM) | -36.78% |
| 股东权益报酬率 (ROE TTM) | -245.59% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | IGM Biosciences, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 价值 35% | -2.5 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -2.5 |
| 时机 35% | 0.6 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | 0.0 |
| 技术平均移动指标 参考 | 1.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -36.3% |
| 支柱一致性 | ×1.06 |
| 不计入评分 | |
| 价格波动 参考 | -0.6 |
| 最终评分 | -0.85 |
|
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 37.57% |
| 机构持股比例 | 47.53% |
投资组合